Trial Profile
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms DELIVER
- Sponsors AstraZeneca; AstraZeneca AB
- 01 Dec 2023 Results of a patient level pooled analysis assessing efficacy of Dapagliflozin according to Heart Rate from two clinical trials: DAPA-HF and DELIVER trials published in the Circulation: Heart Failure
- 13 Nov 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure
- 13 Nov 2023 Results of patient-level pooled analysis of the DAPA-HF and DELIVER trials; comparing the baseline characteristics and outcomes by history of CABG and assessing efficacy and safety of dapagliflozin, presented at the American Heart Association Scientific Sessions 2023